Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Arthritis, Rheumatoid 4Lymphoma, Follicular 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × olokizumab × Clear all
NCT01242488 2024-07-17

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

UCB Pharma

Phase 2 Completed
221 enrolled

Arthritis, Rheumatoid

NCT03120949 2023-10-12

CREDO 4

R-Pharm

Phase 3 Completed
2,106 enrolled 30 charts
Lymphoid

Arthritis, Rheumatoid, Lymphoma, Follicular

NCT02760433 2023-09-21

CREDO 3

R-Pharm

Phase 3 Completed
368 enrolled 21 charts

Arthritis, Rheumatoid

NCT01463059 2013-03-25

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

UCB Pharma

Phase 2 Completed
119 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡